ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial Condition

0

ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition

On July28, 2017, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June30, 2017. A copy of the press release is furnished as Exhibit99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

Exhibit No.

Exhibit

99.1

Press Release dated July 28, 2017 (furnished to Item 2.02).

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:

July 28, 2017

By:

/s/ William J. Chase

William J. Chase

Executive Vice President,

Chief Financial Officer

EXHIBITINDEX

Exhibit No.

Exhibit

99.1

Press Release dated July 28, 2017 (furnished
AbbVie Inc. Exhibit
EX-99.1 2 abbv_20170630xexhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 PRESS RELEASE AbbVie Reports Second-Quarter 2017 Financial Results  •Reports Second-Quarter Diluted EPS of $1.19 on a GAAP Basis; Adjusted Diluted EPS of $1.42,…
To view the full exhibit click here

About ABBVIE INC. (NYSE:ABBV)

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.